NKTR (STOCKS)
Nektar Therapeutics
$66.465900
+10.465900 (+18.69%)
Prev close: $56.000000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Howard W. Robin
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,051.42M
- Employees
- 61
- P/E (TTM)
- -7.06
- P/B (TTM)
- 12.93
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
6
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-1.87 | $-2.74 | +0.8682 | +31.71% |
|
Jun 2025 (Q2)
|
$-2.95 | $-3.10 | +0.1457 | +4.71% |
|
Mar 2025 (Q1)
|
$-3.60 | $-2.51 | -1.0864 | -43.22% |
|
Dec 2024 (Q4)
|
$-2.40 | $-2.57 | +0.1742 | +6.77% |
Financial Statements
| Revenues | $62.60M |
| Benefits Costs and Expenses | $176.38M |
| Cost Of Revenue | $7.98M |
| Costs And Expenses | $160.69M |
| Nonoperating Income/Loss | -$15.69M |
| Operating Expenses | $152.71M |
| Depreciation and Amortization | $1.17M |
| Research and Development | $116.36M |
| Other Operating Expenses | $35.18M |
| Operating Income/Loss | -$98.09M |
| Income/Loss From Continuing Operations After Tax | -$113.36M |
| Income/Loss From Continuing Operations Before Tax | -$113.78M |
| Income Tax Expense/Benefit | -$428.00K |
| Net Income/Loss | -$120.74M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$120.74M |
| Net Income/Loss Available To Common Stockholders, Basic | -$120.74M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.55 |
| Diluted Earnings Per Share | $0.55 |
| Basic Average Shares | 207,758,126 |
| Diluted Average Shares | 207,758,126 |
| Assets | $301.35M |
| Current Assets | $281.36M |
| Noncurrent Assets | $19.99M |
| Fixed Assets | $2.83M |
| Other Non-current Assets | $17.16M |
| Liabilities | $216.26M |
| Current Liabilities | $66.34M |
| Accounts Payable | $15.56M |
| Wages | $8.61M |
| Other Current Liabilities | $42.17M |
| Noncurrent Liabilities | $149.92M |
| Equity | $85.09M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $85.09M |
| Liabilities And Equity | $301.35M |
| Net Cash Flow From Operating Activities | -$189.74M |
| Net Cash Flow From Operating Activities, Continuing | -$189.74M |
| Net Cash Flow From Investing Activities | $58.65M |
| Net Cash Flow From Investing Activities, Continuing | $58.65M |
| Net Cash Flow From Financing Activities | $141.98M |
| Net Cash Flow From Financing Activities, Continuing | $141.98M |
| Exchange Gains/Losses | $39.00K |
| Net Cash Flow | $10.92M |
| Net Cash Flow, Continuing | $10.88M |
| Comprehensive Income/Loss | -$121.04M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$121.04M |
| Other Comprehensive Income/Loss | -$299.00K |